Evogene Ltd. | CIK:0001574565 | 3

  • Filed: 3/30/2018
  • Entity registrant name: Evogene Ltd. (CIK: 0001574565)
  • Generator: GoXBRL
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1574565/000117891318001042/0001178913-18-001042-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1574565/000117891318001042/evgn-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001574565
  • Open this page in separate window: Click
  • ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory

    q.
    Share-based payment transactions:

    The Company's employees and consultants are entitled to remuneration in the form of equity-settled share-based payment transactions.

    Equity-settled transactions:

    The cost of equity-settled transactions with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable option pricing model.

    As for consultants, the cost of the transactions is measured at the fair value of the services received as consideration for equity instruments granted.

    The cost of equity-settled transactions is recognized in profit or loss together with a corresponding increase in equity during the period which the performance and/or service conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award ("the vesting period"). The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects the extent to which the vesting period has expired and the Company's best estimate of the number of equity instruments that will ultimately vest. No expense is recognized for awards that do not ultimately vest.

    If the Company modifies the conditions on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement or is otherwise beneficial to the employee or other service provider at the modification date.